Dr. Gulati on the Prevalence of TSC1 and TSC2 Mutations in Solid Tumors

Gunsagar Gulati, MD, discusses the prevalence of TSC1 and TSC2 mutations in solid tumors.

Gunsagar Gulati, MD, resident physician, Internal Medicine, Brigham and Women's Hospital, discusses the prevalence of TSC1 and TSC2 mutations in solid tumors.

An analysis of 16 solid tumor types from more than 29,000 patients from The Cancer Genome Atlas and AACR GENIE database examined the occurrence of TSC1 and TSC2 mutations. Surprisingly, TSC1 and TSC2 mutations were found to be more frequent than initially hypothesized, Gulati said. Moreover, it was found that over 11,000 patients every year have TSC1 and TSC2 mutations, and developing a drug that targets these alterations could benefit these patients, Gulati explains.

The rationale of the evaluation was to compare the prevalence of TSC1 and TSC2 mutations with genetic markers that have targeted therapies, such as KRAS, HER2, and BRAF, Gulati continues. The findings showed the frequency of TSC1 and TSC2 mutations ranked higher than some other targeted markers, which represents an area of opportunity for treating these patients, Gulati concludes.

Related Videos
Consuelo Bertossi, MD
Michael R. Grunwald, MD, FACP
Sundar Jagannath, MBBS
Kevin Kalinsky, MD, MS,
Aaron Gerds, MD
Paolo Tarantino, MD
Chinmay Jani, MD, clinical fellow, Hematology & Oncology, Sylvester Comprehensive Cancer Center at the University of Miami/Jackson Memorial Hospital
Shella Saint Fleur-Lominy, MD, PhD
Benjamin Levy, MD
Nader Sanai, MD, chief, Neurosurgical Oncology, director, Ivy Brain Tumor Center, Barrow Neurological Institute